Yarrow Bioscience YARW Income Statement (2016-2026)

NASDAQ YARW
$29.11 -0.19 (-0.65%)
At close: Sep 9, 2026 · 4:00 PM EDT
Reported Financials

Yarrow Bioscience Quarterly Income Statement

Periods 38 quarters
Latest Jun 2026

Yarrow Bioscience reported revenue of $0.10M and net income of -$3.01M for the quarter ended Jun 2026, down 50.5% year over year. This income statement covers 38 quarters of results from Dec 2016 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Income Statement Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Dec2025 Mar2026 Jun2026
Revenue & cost
Revenue
0.29M0.13M0.27M0.18M0.13M0.17M0.03M0.10M0.14M0.11M0.08M0.10M0.20M0.12M0.08M0.20M0.10M0.10M0.10M
Cost of RevenueCost of Rev
0.80M1.05M0.90M
Gross Profit
-0.50M-0.92M-0.63M
Operating items
Research & DevelopmentR&D
5.05M5.92M4.32M4.45M4.11M5.55M4.28M2.73M7.23M3.32M3.02M3.71M7.31M10.25M9.68M6.12M4.88M0.82M0.79M
Selling, General & AdministrativeSG&A
4.79M4.98M4.79M4.42M4.30M3.95M3.71M3.24M3.22M3.03M3.88M3.77M3.29M2.96M3.17M3.27M2.73M3.08M2.41M
Other Operating ExpensesOther Opex
Operating ExpensesOpex
9.84M10.90M9.12M8.87M8.41M9.50M7.99M5.97M10.45M6.35M6.91M7.48M10.59M13.21M12.85M9.40M7.61M3.90M3.20M
Operating IncomeOp. Inc
-9.54M-10.77M-8.85M-8.69M-8.29M-9.33M-7.98M-5.88M-10.32M-6.23M-6.83M-7.38M-10.40M-13.09M-12.77M-9.20M-7.54M-3.82M-3.10M
EBIT
-9.54M-10.77M-8.85M-8.69M-8.29M-9.33M-7.98M-5.88M-10.32M-6.23M-6.83M-7.38M-10.40M-13.09M-12.77M-9.20M-7.54M-3.82M-3.10M
Non-operating items
Non Operating Interest Expenses
1.07M3.47M
Interest & Investment IncomeInt & Inv Inc
Other Non Operating IncomeOther Non Op Inc.
-0.07M-0.04M0.03M-0.00M0.05M0.08M0.24M0.26M0.28M0.16M0.68M1.14M1.00M0.93M0.76M0.59M1.79M0.23M0.20M
Net income details
EBT
-10.69M-14.28M-8.82M-8.69M-8.23M-9.26M-7.75M-5.61M-10.04M-6.07M-6.15M-6.24M-9.39M-12.16M-12.01M-8.60M-5.75M-3.58M-2.90M
Tax ProvisionsTaxes
-0.45M0.01M0.00M
Profit After TaxPAT
-19.92M-21.29M-11.57M-8.69M-8.48M-9.46M-7.76M-5.62M-10.06M-6.58M-6.19M-6.34M-9.41M-12.16M-12.03M-8.63M-5.76M-3.60M-3.01M
Income from Continuing OperationsIncome (Continuing)
-10.69M-14.28M-8.37M-8.69M-8.23M-9.26M-7.76M-5.61M-10.04M-6.07M-6.15M-6.24M-9.39M-12.16M-12.01M-8.60M-5.75M-3.58M-2.90M
Income from Discontinued OperationsIncome (Discontinued)
-9.24M-7.01M-3.20M13.36M-0.24M-0.20M-2.18M-0.01M-0.02M-0.51M-0.04M-0.01M-0.01M-0.01M-0.01M-0.01M-0.11M
Consolidated Net IncomeConsol Net Inc.
-19.92M-21.29M-11.57M4.67M-8.48M-9.46M-9.95M-5.62M-10.06M-6.58M-6.19M-6.25M-9.41M-12.16M-12.02M-8.61M-5.75M-3.58M-3.01M
Income towards Parent CompanyParent Net Inc
-19.92M-21.29M-11.57M4.67M-8.48M-9.46M-9.95M-5.62M-10.06M-6.58M-6.19M-6.25M-9.41M-12.16M-12.02M-8.61M-5.75M-3.58M-3.01M
Net Income towards Common StockholdersNet Income
-19.92M-21.29M-11.57M4.67M-8.48M-9.46M-9.95M-5.62M-10.06M-6.58M-6.19M-6.25M-9.41M-12.16M-12.02M-8.61M-5.75M-3.58M-3.01M
Additional items
EPS (Basic)
-19.38-20.46-11.244.22-7.32-8.16-156.07-86.36-153.60-100.30-30.12-7.34-11.04-14.27-14.11-10.09-6.73-4.19-3.50
EPS (Diluted)
-19.38-20.46-11.244.22-7.32-8.16-156.07-86.36-153.60-100.30-30.12-7.34-11.04-14.27-14.11-10.09-6.73-4.19-3.50
Shares Outstanding
1.03M1.04M1.03M1.11M1.16M1.16M0.06M0.07M0.07M0.07M0.21M0.85M0.85M0.85M0.85M0.85M0.86M0.86M0.86M0.86M
Shares Outstanding (Diluted)Shares Outstanding (Dil.)
1.03M1.04M1.03M1.11M1.16M1.16M0.06M0.07M0.07M0.07M0.21M0.85M0.85M0.85M0.85M0.85M0.86M0.86M0.86M0.86M
Shares Outstanding (Entity)Shares Outstanding (Entity.)
1.03M1.07M1.07M1.16M1.16M1.16M0.06M0.07M0.07M0.07M0.21M0.85M0.85M0.85M0.85M0.85M0.86M0.86M0.86M0.86M
EBITDA
-9.54M-10.77M-8.85M-8.69M-8.29M-9.33M-7.98M-5.88M-10.32M-6.23M-6.83M-7.38M-10.40M-13.09M-12.77M-9.20M-7.54M-3.82M-3.10M
Interest ExpensesInt Expense
1.07M3.47M
Tax Rate
5.08%-0.17%-0.03%